• 1:中国医师协会心血管内科医师分会结构性心脏病专业委员会
• 2:亚太结构性心脏病青年俱乐部(大陆)编写组

摘要(Abstract)：

<正>结构性心脏病学是近十几年来提出的介入心脏病学的一个亚专科。结构性心脏病一般指心电疾病和冠状动脉疾病以外任何与心脏和临近心脏的大血管结构有关的疾病,其特点是可通过(介入技术)矫正或改变心脏和大血管结构来治疗[1]。结构性心脏病学发展迅速,各种新技术层出不穷。自2020年起,中国医师协会心血管内科医师分会结构性心脏病专业委员会、亚太结构性心脏病青年俱乐部(大陆)在年终会对本年度结构性心脏病学发展按主要技术方向做一个年度总结报告[2]。

关键词(KeyWords)： 结构性心脏病;介入治疗;经导管主动脉瓣置换术

Abstract:

Keywords:

基金项目(Foundation):

作者(Author):

参考文献(References)：

• [1]葛均波.结构性心脏病的定义、范畴以及其现状和未来[J].上海医学,2021,44(4):217-220.
• [2]中国结构性心脏病介入治疗进展报告编写组.中国结构性心脏病介入治疗进展报告2020[J].中国循环杂志,2021,36(9):833-840.
• [3]Vahanian A,Beyersdorf F,Praz F,et al.2021 ESC/EACTS guidelines for the management of valvular heart disease[J/OL].Eur Heart J,2021:ehab395.
• [4]Michelena HI,Della Corte A,Evangelista A,et al.International consensus statement on nomenclature and classification of the congenital bicuspid aortic valve and its aortopathy,for clinical,surgical,interventional and research purposes[J/OL].J Thorac Cardiovasc Surg,2021,162(3):e383-e414.
• [5]Collet JP,Berti S,Cequier A,et al.Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis:the randomized ATLANTIS trial[J].Am Heart J,2018,200:44-50.
• [6]Van Mieghem NM,Unverdorben M,Hengstenberg C,et al.Edoxaban versus Vitamin K antagonist for atrial fibrillation after TAVR[J].N Engl J Med,2021,385(23):2150-2160.
• [7]Session 1:tailoring mitral valve repair:MitraClip G4 review& evolution of TEER [EB/OL].(2021-06-20)[2022-01-27].https://www.tctmd.com/slide/session-l-tailoring-mitral-valverepar-mitraclip-g4-review-evolution-teer.
• [8]Zahr F,Song HK,Chadderdon SM,et al.Thirty-day outcomes following transfemoral transseptal transcatheter mitral valve replacement:intrepid TMVR early feasibility study results[J].JACC Cardiovasc Interv,2022,15(1):80-89.
• [9]Nickenig G,Weber M,Schüler R,et al.Two-year outcomes withthe cardioband tricuspid system from the multicentre,prospective TRI-REPAIR Study[J/OL].EuroIntervention,2021,16(15):e1264-e1271.
• [10]Fam NP,von Bardeleben RS,Hensey M,et al.Transfemoral transcatheter tricuspid valve replacement with the EVOQUE system:a multicenter,observational,first-in-human experience[J].JACC Cardiovasc Interv,2021,14(5):501-511.
• [11]Lu FL,Ma Y,An Z,et al.First-in-man experience of transcatheter tricuspid valve replacement with luxvalve in high-risk tricuspid regurgitation patients[J].JACC Cardiovasc Interv,2020,13:1614-1616.
• [12]Osmancik P,Tousek P,Herman D,et al.Interventional left atrial appendage closure vs.novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation(prague-17study)[J].Am Heart J,2017,183:108-114.
• [13]Lakkireddy D,Thaler D,Ellis CR,et al.Amplatzer amulet left atrial appendage occluder versus watchman device for stroke prophylaxis(Amulet IDE):a randomized,controlled trial[J].Circulation,2021,144(19):1543-1552.
• [14]Verma S,Bhatt DL,Tseng EE.Time to remove the left atrial appendage at surgery:LAAOS Ⅲ in perspective[J].Circulation,2021,144(14):1088-1090.
• [15]Du X,Guo L,Xia S,et al.Atrial fibrillation prevalence,awareness and management in a nationwide survey of adults in China[J].Heart,2021,107(7):535-541.
• [16]Liu Y,Xu C,Ding P,et al.Transcatheter closure of mitral paravalvular leak via multiple approaches[J].J Interv Cardiol,2021,2021:6630774.
• [17]蒲俊舟,吴文辉,科雨彤,等.心脏瓣膜替换术后瓣周漏的介入与外科治疗的比较观察[J].中华医学杂志,2021,101(16):1160-1164.